Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00332514 · ClinicalTrials.gov registry record · Phase 2

Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care

A Phase 2 study of Readmission, Hospital, sponsored by Boston Medical Center.

Completed
Registry status
Phase 2
Development phase
200
Enrollment target
1
Study location

NCT00332514 is a Phase 2 study of Readmission, Hospital that has completed, run by Boston Medical Center. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00332514, a Phase 2 study of Readmission, Hospital, has completed, sponsored by Boston Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The purpose is to analyze whether a follow-up telephone call by a pharmacist after patient discharge from the hospital can improve patient outcomes. Patients will be interviewed via telephone within 72 hours of being discharged home from the hospital. Patients will be questioned on three main topics. They are: 1. Medical care 2. Medications 3. Follow-up appointments The purpose is to find out if people understand discharge medications, have obtained those medications, are having any problems with their medications and have scheduled necessary follow-up appointments. It will be determined if a telephone call by a pharmacist will prevent patients from needing to go to the Emergency Room or being admitted back to the hospital.

Conditions Studied

Interventions

  • BEHAVIORAL telephone call by a pharmacist

Study Locations (1)

Massachusetts

  • Boston Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2004-03
Est. Completion 2008-01
Phase Phase 2

Sponsor

Boston Medical Center

253 total trials

What the Registry Record Tells You About NCT00332514

The ClinicalTrials.gov registry entry for NCT00332514 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Readmission, Hospital appearing as the primary indexed condition, and to 1 intervention - of which telephone call by a pharmacist is the first listed.

NCT00332514 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00332514 about?

NCT00332514 is a clinical study titled "Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care". The purpose is to analyze whether a follow-up telephone call by a pharmacist after patient discharge from the hospital can improve patient outcomes. Patients will be interviewed via telephone within 72 hours of being discharged home from the hospital. Patients will be questioned on three main topic...

What is the current status of trial NCT00332514?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2004-03. Estimated completion is 2008-01.

What conditions does trial NCT00332514 study?

This clinical trial studies the following conditions: Readmission, Hospital.

What interventions are being tested in trial NCT00332514?

The interventions under investigation include: telephone call by a pharmacist (BEHAVIORAL).

Who is sponsoring clinical trial NCT00332514?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00332514 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Readmission, Hospital

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.